The MDR project (HIV multidrug resistance pathways in the EuResist Integrated DataBase) aims at estimating the prevalence and trend over time of MDR (multidrug resistance) in HIV patients, using descriptive statistics, retaining high value because of the large sample size and wide representativeness of the EIDB.

 

In addition, the project aims at identifying factors associated with development of MDR and deriving successful treatment strategies in MDR patients, based on GSS of possible rescue therapies: these challenging and ambitious tasks will benefit from machine learning approaches and the use of probabilistic models, under the responsibility of a multidisciplinary team with excellent specific and cross-talk capability, well-established through decennial cooperation within the EuResist consortium. 

The MDR project started at March 2019. The study group includes clinicians, virologists and modelers with specific strong expertise in HIV drug resistance: Dr. A. Sönnerborg (KI), Dr. M. Zazzi (UNISI), Dr. R. Kaiser (UNIKOELN), : Dr. A.M. Vandamme (Rega Institute)

NEW!

The Poster "4-Class Resistance is rare in treatment experienced patients across Europe" has been accepted at the Conference on Retroviruses and Opportunistic Infections (CROI) 2020

Project supported by a grant from ViiV Healthcare S.r.l.

PUBLICATIONS

In press: In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in multidrug resistant HIV-1 infected patients. F. Saladini, A. Giannini, F. Giammarino, F. Maggiolo, F. Vichi, G.M. Corbelli, A. Galli, A. Bigoloni, A. Poli, M.M. Santoro, M. Zazzi, A. Castagna.

Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations. F. Saladini, A. Giannini, A. Boccuto, F. Dragoni, A. Appendino, E. Albanesi, I. Vicenti, M. Zazzi. 2020.
Antimicrob Agents Chemother 64:e01717-19. https://doi.org/10.1128/AAC.01717-19.

4-Class Resistance is rare in treatment experienced patients across Europe

M. Zazzi, A.M. Vandamme, B. Rossetti, M. Fabbiani, F. Incardona, K. Theys, A. Abecasis, C. Devaux, R. Kaiser, A. Sönnerborg, G. Pasculli, J. Vercauteren 
for the EuResist Network study group

CROI 2020

CROI_2020-Poster-EuResist_V08_uploaded.j
 

EuResist Network GEIE
Via Guido Guinizelli, 98/100 - 00152 Rome - Italy
Tel. +39 06 5758926 - Fax +39 06 62207168

VAT N. 09950311002 / reg. N° RM-1199300


CEO: Dr. Francesca Incardona

e-mail: f.incardona@euresist.org

EuResist Network GEIE
© 2017 All Right Reserved